Investors

Second US Office for ImmunoPrecise Antibodies, Ltd. in Cambridge, Massachusetts.

VICTORIA, February 14, 2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) has announced that they have opened a new subsidiary office in Cambridge, Massachusetts.

ImmunoPrecise Antibodies Ltd is a Canadian contract research organization providing a range of services, including antibody discovery, manufacturing, optimization, engineering and pre-clinical studies.

“With production sites in Canada and the Netherlands, and the executive headquarters in the North Dakota, establishing a base in the Boston / Cambridge area, a powerhouse for biotech and pharma, is a strategic next step for IPA. We already have a strong base of both European and US clients, and this move will help us enhance and grow our Boston area business and relationships”, said Jennifer bath, CEO of IPA.

The new office is located at One Broadway, 14th floor, Cambridge, MA 02142 and will initially be staffed for sales and business development initiatives.

“There is a tremendous demand for pioneering antibody discovery and development services in the greater Boston area, the largest US biotech hub, and we are excited to provide day-to-day access to our clients and prospective clients as we continue to offer an unparalleled continuum of antibody discovery and downstream technologies,” stated Dr. Jennifer Bath, CEO and President of IPA.

About ImmunoPrecise Antibodies Ltd.

ImmunoPrecise is a full-service, therapeutic antibody discovery company focused on the next generation of antibody discovery, to deliver the most therapeutically-relevant antibodies, in a shorter period of time, with the highest probability of succeeding to clinical trials.

ImmunoPrecise operates from state-of-the-art laboratory facilities located at the Vancouver Island Technology Park in Victoria, British Columbia, in collaboration with its wholly-owned subsidiary operations at U-Protein Express B.V., in the Life Science Incubator, Utrecht, and ModiQuest Research, Oss, both in the Netherlands. The Company operates globally to offer antibody services from target analysis to pre-clinical studies.

The services offered to clients include antibody discovery against a broad spectrum of antigens, including challenging targets. Amongst these services, the Company offers hyridoma production, B-cell services, and a variety of phage display platforms. The Company also provides a broad range of supporting services including immunologically-based assays, recombinant protein manufacturing, humanization, optimization, stable cell line development, and advanced solutions to challenges faced by clients in antibody-related research and development. The antibodies produced by ImmunoPrecise target a wide variety of therapeutic, diagnostic and research applications.

For further information please contact:

 

ImmunoPrecise Antibodies Ltd.

Jennifer Bath, CEO and President

3204-4464 Markham Street

Victoria, BC V8Z 7X8

www.immunoprecise.com

 

For investor relations please contact:

Frederick Chabot

Phone: 1-438-863-7071

Email: frederick@contactfinancial.com

Contact Financial Corp.

1450 – 701 West Georgia St.

Vancouver, BC V7Y 1G5

 

Forward Looking Information

This news release contains statements that, to the extent they are not recitations of historical fact, may constitute “forward-looking statements” within the meaning of applicable Canadian securities laws. The Company uses words such as “may”, “would”, “could”, “will”, “likely”, “expect”, “believe”, “intend” and similar expressions to identify forward-looking statements. Any such forward-looking statements are based on assumptions and analyses made by ImmunoPrecise in light of its experience and its perception of historical trends, current conditions and expected future developments. However, whether actual results and developments will conform to ImmunoPrecise’s expectations and predictions is subject to any number of risks, assumptions and uncertainties. Many factors could cause ImmunoPrecise’s actual results to differ materially from those expressed or implied by the forward-looking statements contained in this news release. Such factors include, among other things, actual revenues and earnings for IPA being lower than anticipated, and those risks and uncertainties described in ImmunoPrecise’s annual management discussion and analysis for the fiscal year ended April 30, 2017 which can be accessed at www.sedar.com. The “forward-looking statements” contained herein speak only as of the date of this press release and, unless required by applicable law, ImmunoPrecise undertakes no obligation to publicly update or revise such information, whether as a result of new information, future events or otherwise.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.